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Background & Aims: The intestinal microbiota is closely associated with resident memory 
lymphocytes in mucosal tissue. We sought to understand how acquired cellular and humoral 
immunity to the microbiota differ in health versus inflammatory bowel disease (IBD).  
Methods: Resident memory T-cells (Trm) in colonic biopsies and local antibody responses to 
intraepithelial microbes were analyzed. Systemic antigen-specific immune T- and B-cell 
memory to a panel of commensal microbes was assessed.  
Results: Systemically, healthy blood showed CD4 and occasional CD8 memory T-cell 
responses to selected intestinal bacteria but few memory B-cell responses. In IBD, CD8 
memory T-cell responses decreased although B-cell responses and circulating plasmablasts 
increased. Possibly secondary to loss of systemic CD8 T-cell responses in IBD, dramatically 
reduced numbers of mucosal CD8+ Trm and γδ T-cells were observed. IgA responses to 
intraepithelial bacteria were increased. Colonic Trm expressed CD39 and CD73 
ectonucleotidases, characteristic of regulatory T-cells. Cytokines/factors required for Trm 
differentiation were identified, and in vitro-generated Trm expressed regulatory T-cell 
function via CD39. Cognate interaction between T-cells and dendritic cells induced T-bet 
expression in dendritic cells, a key mechanism in regulating cell-mediated mucosal 
responses.  
Conclusions: A previously unrecognized imbalance exists between cellular and humoral 
immunity to the microbiota in IBD, with loss of mucosal T-cell-mediated barrier immunity 
and uncontrolled antibody responses. Regulatory function of Trm may explain their 
association with intestinal health. Promoting Trm and their interaction with dendritic cells 
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rather than immunosuppression may reinforce tissue immunity, improve barrier function 
and prevent B-cell dysfunction in microbiota-associated disease and IBD etiology. 
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Introduction 
Large numbers of lymphocytes reside in the intestinal mucosa and play a key role in barrier 
function and immune surveillance. Immunity against infection is provided by long-lived 
memory T-cells reactive to foreign antigens as well as antibody1. Memory T-cells can be 
broadly categorized into circulating (central memory and effector memory) and tissue-
resident, non-recirculating cells called resident memory T-cells (Trm)2. Trm provide potent 
barrier immunity in mucosal tissues due to their high motility, rapid re-activation of effector 
function and ability to recruit further immune responses via cytokine (e.g. IFN-γ) secretion. 
However, the role of Trm in human disease is unclear, and how they interact with resident 
microbes that make up the intestinal microbiota is not understood. 
Inflammatory bowel disease (IBD) is thought to be perpetuated by intestinal microbial 
dysbiosis leading to episodic colitis (ulcerative colitis, UC) or localized inflammation 
anywhere along the gastrointestinal (GI) tract (Crohn’s disease, CD), mediated by Th17 or 
other subsets of CD4 T-cells3,4. Disease etiology involves interaction of multiple genetic 
susceptibilities with environmental factors including diet and lifestyle factors that can affect 
the microbiota. However, most studies to date have focussed on sequence-based profiling 
of microbiomes in disease; how different microbial species interact with the immune system 
is not well understood. Mouse studies indicate the colonic microbiota is essential for 
recruiting sufficient CD4 Foxp3-expressing regulatory T-cells (Treg) to the colon to prevent 
inflammation5,6. This suggests that IBD results from a failure of Treg-mediated tolerance to 
commensals in the GI tract.  
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Here we studied memory T-cell responses to a panel of intestinal commensal bacteria in IBD 
patients and healthy controls, and analyzed Trm populations in the epithelium and lamina 
propria colonic tissue where they are in close proximity to mucosa-associated microbes. Our 
data show that underlying disease in human IBD is associated with reduced CD8 T-cell 
responses to commensal bacteria leading to Trm deficiency in the colon, and chronic B-cell 
activation and excess IgA secretion associated with a loss of barrier immunity. We also show 
that human Trm express Treg function and propose specific mechanisms to explain how loss 
of Trm:dendritic cell interaction could contribute to the development of inflammatory 
disease.  
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Methods 
Study Design 
The study aimed to determine the role of resident memory T cells in IBD. Donors (age 16-80) 
were recruited to the study from outpatient clinics of St Mark’s Hospital and included those 
with a diagnosis of CD or UC, and healthy donors undergoing investigative endoscopy. None 
of the CD patients had a history of obstruction, perianal disease or ileitis alone. Patients 
were recruited over a fixed period determined by ethical permission, no data were excluded 
at the end of the study. Additional healthy blood donors were recruited from hospital staff 
and visitors. Ethics approval was obtained from the Health Research Authority UK and 
London Brent Research Ethics Committee. Written informed consent was received from 
participants prior to inclusion in the study. 
Colonic intraepithelial lymphocytes (IEL), lamina propria lymphocytes (LPL) and 
intraepithelial microbe (IEM) isolation 
5 left colon and 5 right colon biopsies (10mg tissue each) were obtained from 
macroscopically non-lesional tissue sites at routine colonoscopy in all patients as described7. 
IEL and IEM were released from biopsies using DTT/EDTA and harvested by centrifugation at 
300g (5min). IEM were obtained by centrifugation of resulting supernatants at 4500g 
(20min). LPL were obtained by collagenase digestion of remaining tissue; all cells were 
phenotyped and counted by flow cytometry. Cells were washed in PBS and stained for 
viability using LIVE/DEAD Fixable-near-IR stain (ThermoFisher) before addition of surface-
staining antibodies in fetal calf serum. In some cases cells were then fixed/permeabilized for 
intranuclear staining using the Foxp3 buffer set (ThermoFisher, as instructions). Antibodies 
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used are listed in supplementary file 1. All samples were analyzed on a BD Biosciences FACS 
Canto II and data analyzed by FlowJo software (Tree Star), with volumetric sampling 
determined using Perfect-Count microspheresTM (Cytognos, S.L). 
In vitro differentiation of Trm-like cells from human PBMC 
Naïve CD8 T-cells were purified by magnetic selection from healthy donor PBMC using the 
naïve CD8 T-cell isolation kit (Miltenyi Biotec) and were >98% CD8+ and >98% CD45RA+. 
Naïve CD8 T-cells were stimulated with plate-bound anti-CD3 (1µg/ml), soluble anti-CD28 
(1µg/ml) and IL-2 (5ng/ml, Peprotech). Further additions of TGF-β (3 ng/ml, R&D Systems), 
IFN-β (10 ng/ml, R&D), all-trans retinoic acid (ATRA, 10nM, Sigma), FICZ (AhR agonist, 
100nM, Tocris Bioscience) were made at the start of the 7 day culture. Cultured cells were 
washed in PBS, stained for viability and surface or intracellular markers as above. Tc1/Trm-
like cells were analysed for cytokine production by re-stimulation with PMA 
(20ng/ml)+ionomycin (400ng/ml)+monensin (3µM) for 4h before staining using Foxp3 
staining buffer set. 
Commensal-specific T and B-cell memory proliferative responses 
Commensal species were isolated from the cecum of healthy donors with the exception of 
Collinsella aerofaciens, which was from feces8,9,10. Strains were grown anaerobically in 
Hungate tubes containing Wilkins-Chalgren broth (37°C for 24h). Aliquots (1ml) were 
centrifuged (13,000rpm for 10 min), supernatants removed and cell pellets snap-frozen with 
dry ice before storage at -80°C. PBMC were obtained over Ficoll gradients and labelled with 
CellTrace VioletTM (1µM, Life Technologies) according to manufacturer’s instructions, then 
cultured at 4x106/ml in XVIVO15 serum-free medium (Lonza, +50µg/ml gentamycin (Sigma) 
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and penicillin/streptomycin (Life Technologies, 1/100)). 2x105 killed bacteria from 19 species 
(as in Fig 5) were added to 0.2ml cultures and microbe-specific CD4+/CD8+ T-cell and B-cell 
responses were determined after 7 days culture. Cultured cells were analyzed by staining 
with LIVE/DEAD stain, CD4/CD8/CD19/integrin-β7/CLA/CD39. 
Suppression assays 
A fraction of healthy donor PBMC were cryopreserved before isolation of naïve CD8 T-cells 
and differentiation into Tc1- or Trm-like cells as described above. Cells were cultured at 
0.5x106/ml in 0.4ml cultures; Tc1 cells were generated with anti-CD3/28+IL-2 only and Trm-
like cells with addition of TGF-β, IFN-β, ATRA and FICZ. After 7 days cells were washed and 
autologous PBMC thawed before labelling with CellTrace VioletTM. Labelled target cells were 
cultured in U-bottom wells (0.2ml XVIVO-15) at 106/ml with or without addition of 
unlabelled Tc1/Trm cells and CD39 inhibitor ARL67156 (200µM, Tocris Bioscience). Cells 
were stimulated by addition of SEB (0.1µg/ml, Sigma) and stained after 4 days with 
LIVE/DEAD stain, CD3/CD4/CD8/ CD25. Cells were gated for CellTrace Violet+ CD8+ T-cells 
and fractions of cells which had divided and upregulated CD25 assessed. 
Induction of transcription factors and cytokines in DC 
PBMC from healthy donors were cultured at 106/ml in RPMI-1640 medium (Sigma) 
supplemented with 10% newborn calf serum (Sigma) and antibiotics as above. LPS (1µg/ml), 
SEB (10ng/ml, both Sigma), anti-IFN-γ (50µg/ml) or isotype control IgG1 were added. After 
overnight culture all cells were stimulated with LPS+poly I:C (1µg/ml, Sigma) + monensin 
(3µM) for a further 4h and stained for lineage markers, HLA-DR/CD123/CD11c/T-bet/TNF-α 
/IFN-α and LIVE/DEAD stain using Foxp3 buffer set. Gating for singlet mDC and pDC was 
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performed as shown in supplementary file 1. Strict gating for CD11c-negative cells was used 
to exclude mDC precursors from the pDC gate – this was confirmed by lack of staining for 
CD33, CX3CR1 and Axl. 
Measurement of antibody responses 
IEM were labelled with SYBR Green DNA stain (Life Technologies, 1/100,000), anti-IgA-
APC/anti-IgG-APC/Cy7 and analyzed by flow cytometry to determine proportion (%) of 
bacteria coated with antibodies in the gut. Circulating antibodies to commensal species 
were determined by incubation of plasma (1/10 in 0.1% BSA, 0.5ml) with 1x105 bacteria 
(30min), followed by centrifugation (12,000g, 10 min) and staining as for IEM (or isotype 
controls for each sample). Intact microbes were gated according to SYBR Green, and ratio of 
geometric mean fluorescence intensity of staining for test sample vs isotype control was 
used as measure of antibody titre. Plasma IgG antibodies to viruses were measured using 
ELISA kits from Abcam according to instructions. 
Statistical analysis 
GraphPad Prism 7 software (GraphPad, San Diego, CA) was used to plot and analyze the 
data. Clinical data were analyzed by one-way ANOVA or where populations were skewed, 
Kruskal-Wallis tests. For in vitro experiments, data were analyzed using two-tailed paired t 
tests or one-way ANOVA for multiple experimental conditions. P values less than 0.05 were 
considered significant and indicated by: *:p<0.05; **:p<0.01; ***:p<0.001. 
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Results 
Human colonic Trm are identified by CD103 and Runx3 and express Treg markers CD39 and 
CD73 
To evaluate the role of Trm in IBD, we first identified Trm in intraepithelial lymphocytes (IEL) 
and lamina propria lymphocytes (LPL) from healthy control (HC), CD and UC colonic biopsies 
(non-inflamed tissue; clinical and demographic patient characteristics are shown in Table 1). 
In healthy IEL (Fig 1a) all T-cells including CD8+ or γδ T-cells, expressed the CD69 putative 
Trm marker.  However, CD103 distinguished Trm from effector memory T-cells, which was 
confirmed by their intranuclear expression of the Runx3 transcription factor, which controls 
the Trm transcriptional program in mice11. A fraction of Trm expressed T-bet, which controls 
the Th1 program of differentiation12. In LPL (Fig 1b), main populations were CD4+ and CD8+ 
T-cells and the latter not only contained a much larger proportion of CD103+ Trm-like cells 
but also had higher levels of Runx3 and T-bet than their CD4 counterparts. IEL lacked CD4 
cells and no γδ T-cells were found in LPL.  Trm and γδ T-cells expressed high levels of the 
Treg markers CD39 and CD73, suggesting immunosuppressive function (Figs 1c/1d). CD8 
Trm were nearly all conventional T-cells expressing CD8αβ heterodimer (Fig 1c) and no 
Foxp3 transcription factor (Fig 1d). The vast majority of cells expressing CD39 and CD73 
were also Foxp3- (barring a small fraction of the CD4 Trm) suggesting that the Trm 
themselves contribute to maintaining tissue homeostasis. 
Trm are deficient in Crohn’s disease and ulcerative colitis 
Using this analysis we next compared numbers and phenotype of CD8+ and CD4+ Trm and γδ 
T-cells obtained from right colon of HC, CD and UC donors (Fig 2).  We found a dramatic 
decrease in both CD8 Trm and γδ T-cells in IEL in IBD patients (Fig 2a; 84% and 61% for CD8 
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Trm; 90% and 87% for γδ T-cells in CD and UC, respectively). Both total numbers and 
percentages of Trm relative to total live cells were reduced in IBD donors. The phenotype of 
CD8 Trm was unchanged, but significantly decreased γδ T-cell expression of CD39 was seen 
in UC and CD, suggesting impaired regulatory function. In LPL, there were also fewer Trm, 
although the deficiency was less dramatic than in IEL (61% and 44% for CD8; 28% and 68% 
for CD4 in CD and UC respectively) and did not reach statistical significance for CD4 Trm in 
CD or when expressed in percentage terms (Fig 2b). There was no change in phenotype of 
LPL Trm in disease. Total yields of viable cells in IEL and LPL were unchanged in IBD (Fig 2c); 
thus deficiencies in Trm were selective and could not be explained by loss of epithelium. We 
also found a strong correlation between numbers of CD8 Trm in IEL and γδ T-cells (Fig 2d), 
suggesting co-dependence of these populations. In left colon biopsies we found significantly 
fewer Trm (supplementary file 2, Fig S1) and no significant changes in IBD. The level of Trm 
and γδ T cell deficiency was not related to disease severity, as assessed by macroscopic 
inflammation, in either disease (Fig S2). 
Human Trm development in vitro is controlled by TGF-β, IFN-β, retinoic acid and AhR 
receptor agonists 
To determine possible mechanisms contributing to the deficiency of Trm in IBD we studied 
micro-environmental factors. We developed an in vitro model to induce human Trm-like 
cells from naïve CD8 T-cells purified from healthy donor PBMC (Fig 3). Seven days 
differentiation with anti-CD3/CD28 and IL-2 yielded effector cells with few markers of Trm 
with the exception of the CD73 Treg-associated molecule, and were designated Tc1 type. 
We tested addition of TGF-β, a mucosal cytokine known to promote mouse Trm 
development2; IFN-β, since type 1 interferon in the gut can control colitis13; all-trans retinoic 
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acid (ATRA), known to induce CD10314; and FICZ (5,11-Dihydroindolo[3,2-b]carbazole-6-
carboxaldehyde), an aryl hydrocarbon receptor (AhR) agonist known to promote 
development of IEL15. Different Trm markers were induced differentially by each factor or 
combinations thereof. CD103 expression was dependent on TGF-β alone; CD39 was induced 
by IFN-β and FICZ, as was the Trm transcription factor Runx3. Integrin-β7, not a Trm marker 
but indicative of gut-homing potential, was induced by a combination of TGF-β and ATRA, as 
was CD69, a Trm marker expressed on all intestinal T-cells. Cells expressing all Trm-
associated markers simultaneously (Fig 3b) were maximal using a combination of all four 
factors, which were therefore used to induce Trm-like cells in further functional 
experiments. IL-15, although involved in mouse Trm development, had no effect in this 
model. 
B-cells are dysregulated in quiescent IBD patients 
To determine if reduced CD8 T-cells in colonic tissue of IBD patients was indicative of 
imbalance in cell-mediated immunity versus humoral immunity towards the microbiota, we 
examined proportions of follicular helper (Tfh-like) cells, key inducers of antibody 
production through interaction with B-cells in germinal centres, alongside the gut-homing 
function of T-cells in PBMC (Fig 4a and Fig S3). Tfh-like cells expressing CD4 and CXCR5 were 
unchanged in IBD, as were proportions of integrin-β7+, gut-homing cells. CD8 T-cells did not 
express CXCR5 but showed high levels of integrin-β7 indicating their gut-homing capacity 
was not impaired in IBD. Analysis of B-cell subsets in PBMC (Fig 4b, Table 2) showed 
significantly increased proportions of plasmablasts (CD38hi CD27+ B-cells) in both CD and UC; 
these are a highly activated subset destined to become plasma cells in tissues16. Other B-cell 
subsets, including those switched to IgA or IgG production were unchanged. Consistent with 
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increased B-cell activity, IEM released from colonic biopsies showed significantly higher 
levels of IgA coating in both CD and UC than in HC (Figs 4c/4d), although numbers of 
microbes obtained was unchanged. 
T- and B-cell memory responses to commensal bacteria indicate skewing to humoral 
immunity in IBD 
We then analyzed whether antigen-specific T- and B-cell responses to specific commensal 
bacteria were imbalanced in IBD (Fig 5). We selected 19 commensal strains mainly isolated 
from healthy human cecum, covering as many genera as possible. Killed bacteria were 
added to PBMC for 7 days to identify specific memory CD4/CD8 T-cell or B-cell proliferative 
responses. Results showed responses were highly specific to individual species (Fig 5a/5b) 
and showed high degrees of variability both between individual donors and between HC and 
IBD patients (Fig 5c). Variability within responses of individual donors was noted after 
around one year (Fig S4), indicating such memory is dynamic and not long-term. As 
expected CD4 T-cell responses were the predominant memory response in all groups; 
however, total numbers of positive responses for each donor were unchanged in health vs 
IBD (Fig 5d). By contrast, numbers of the less frequent CD8 T-cell responses were 
significantly reduced in CD compared with HC, with the same trend apparent in UC (Fig 5d). 
B-cell memory responses to bacteria were rare in health but significantly increased in both 
CD and UC (Fig 5d). T-cells proliferating in response to microbes expressed integrin-β7 (gut-
homing marker), CLA (skin-homing) and the CD39 Treg marker, while B-cells only expressed 
CLA in response to microbes (Fig 5a/Fig S3). 
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To investigate a possible link between circulating CD8 memory to commensals and 
recruitment of CD8 Trm to mucosa, we correlated numbers of CD8 responses to the 19 
bacteria with CD8 Trm (IEL) numbers in donors where both blood and biopsies were 
obtained; this indicated a significant positive correlation (Fig 5e). We then examined the 
magnitude of individual responses, as reflected by the proportion of divided cells, which is 
related to antigen-specific precursor frequency. Results for the most immunogenic species 
from each phylum (Fig 5f) show the high level of variability between donors, with a 
significant difference in CD8 response in health vs IBD revealed for Staphylococcus 
epidermidis only, the most immunogenic species. B-cell responses however were 
significantly increased for all species in CD and UC. We also categorized numbers of 
proliferative responses against the four phyla of bacterial species (Fig S5). The same trends 
were observed in all phyla, with the most significant differences in CD8 and B-cell responses 
seen in Actinobacteria and Firmicutes. We also performed assays for commensal-specific 
antibodies in plasma, a more conventional readout for B-cell immunity. Circulating IgG 
specific for the most immunogenic species in the 19-strain panel, as shown in Fig 6a, 
showed that antibody was increased in CD but not UC- indeed levels in UC were the same as 
those in HC and significantly lower than in CD. Antibodies to less immunogenic species were 
detectable but not significantly different between health and IBD. The divergent findings 
with B-cell proliferative response vs circulating IgG were reflected in poor correlations 
between the levels of each in individual donors; the only statistically significant correlation 
was found with E. coli (Fig 6b). Circulating IgA levels were much lower than IgG (Fig S6) or 
undetectable, and did not show significant differences between health and disease.  
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We tested whether immune deviation seen in IBD was specific to microbiota or reflected a 
systemic bias affecting responses to other antigens. We chose to assess responses to classic 
CD8 T-cell-inducing viral antigens. Plasma were assayed for IgG to three non-enteric viruses 
encountered in childhood – varicella-zoster (VZV), measles and respiratory syncytial virus 
(RSV) (Fig 6c). Antibody to VZV showed the same pattern as commensals, with significantly 
increased levels in CD but not UC. Antibodies to measles were detectable in all patient 
groups but did not differ significantly, while few positive titres of RSV IgG were detected. 
Mechanisms of immune deviation in IBD 
The above data clearly indicated a pattern of immune deviation between cellular/cytotoxic 
and humoral immunity to members of the intestinal microbiota as an underlying feature of 
IBD. To examine potential pathogenic mechanisms, we first pursued the hypothesis that 
Trm express regulatory T-cell function. We performed suppression assays using 
conventional Tc1-type CD8 effector cells and Trm-like cells, generated using our in vitro 
model system (Fig 3). The targets used in the assays were autologous PBMC stored in liquid 
nitrogen. Effector cells were added at a 1:4 ratio and an inhibitor of CD39 ectonucleotidase 
activity (ARL67156) used to determine whether suppressive activity was CD39-dependent. 
Target CD8 T-cell proliferation assayed after 4 days revealed suppressive activity in Trm but 
not Tc1 cells, which was partially reversed in the presence of the CD39 inhibitor (Fig 7a). The 
cultured Tc1 and Trm cells were also tested for cytokine production (Fig 7b), which revealed 
that Trm cells had similar capacity for production of pro-inflammatory cytokines IFN-γ, TNF-
α and IL-17 compared to Tc1; however IL-10, the key immunoregulatory cytokine in the GI-
tract17, was significantly increased in Trm cells. Since dendritic cells (DCs) are critical for 
controlling immune deviation and tolerogenic responses and are a target of Treg, we 
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analyzed the interaction between T-cells and DCs, again using a model system with healthy 
PBMC. To stimulate DC: T-cell cognate interactions we used SEB superantigen, compared to 
TLR-mediated DC stimulation using LPS (Fig 7c). We also added LPS + poly I:C + monensin to 
cultures for the final 4h in order to assess DC cytokine production. SEB but not LPS strongly 
induced T-bet transcription factor expression in both myeloid (mDC) and plasmacytoid DC 
(pDC), and those DC expressing T-bet produced less TNF-α and more IFN-α, cytokines with 
opposing roles in colitis13,18-20. In pDC, overall TNF-α production was suppressed by SEB, 
whilst in mDC the reduced levels in T-bet+ DC were counterbalanced by increased TNF-α in 
T-bet- cells. The effect of T-cell:DC interaction on T-bet was partially dependent on IFN-γ, as 
shown by a neutralizing IFN-γ antibody, but effects on cytokine production appeared IFN-γ-
independent. 
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Discussion 
IBD is characterized by acute inflammatory episodes and pathology, and current treatments 
aim to suppress symptoms using a plethora of immunosuppressive strategies. Our studies 
here, focussing mainly on patients with no ulceration (CD) or a Mayo index of 1 or less (UC), 
reveal that underlying disease is characterized by reduced CD8 T-cell immunity to 
commensal microbes associated with a paucity of Trm, potentially explaining the loss of 
barrier immunity which characterizes IBD and drives pathology. Reduced CD8 response can 
also explain the skewing of immunity towards B-cell-mediated antibody production, and loss 
of immunoregulation in the local mucosa due to the reduced numbers of cells expressing 
key Treg molecules CD39 and CD73. The mutually antagonistic relationship between cell-
mediated and humoral immunity was first noted in the 1970s21 and was subsequently 
attributed to the Th1/Th2 axis22,23, as was the hygiene hypothesis in immune-mediated 
disease24. CD8 T-cell responses skew immunity away from humoral and towards cellular 
immunity – our study is the first to examine such responses to the intestinal microbiota in 
humans and points towards novel strategies in IBD treatment. Studies of anti-inflammatory 
commensal-induced pathways in the gut have focussed on CD4 Foxp3 Treg, which form a 
small fraction of the LPL and are absent from IEL in human colon. By contrast, our data show 
Trm could provide a gatekeeper function, controlling access of mucosal antigens to germinal 
centres in lymphoid tissue, and thus Tfh:B-cell interaction, whilst simultaneously controlling 
inflammation through breakdown of extracellular ATP25,26. Runx3 has recently been defined 
as a master transcription factor for development of murine Trm11. Our data show that 
human gut Trm preferentially express Runx3, and further co-express CD39 and CD73, key 
functional molecules on Treg cells27. CD39 is essential for in vitro suppressive activity of 
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Foxp3+ Treg cells due to its ability to degrade extracellular ATP28, which activates DC29, and 
CD73 assists further nucleotide breakdown to adenosine, an immunosuppressive 
molecule30. ATP is released in mucosal tissue by injury but is also secreted by bacteria31, 
explaining the necessity for high expression of these molecules by Trm, especially IEL, in 
comparison to circulating T-cells. IEL and in vitro-derived Trm-like cells expressed lower 
levels of CD73, suggesting that further breakdown of ADP towards adenosine occurs further 
into the mucosa. It should be noted that there are multiple other mechanisms via which 
Treg may express their function32, and we have not been able to directly assess suppressive 
activity in tissue-derived Trm or compare such activity in health vs IBD, due to the low 
numbers available. Therefore, unchanged levels of CD39 and CD73 on Trm in IBD does not 
exclude the possibility of altered function. 
Foxp3+ Treg are critical in systemic tolerance and in establishing tolerance to self-antigens in 
early life33. Foxp3 was not expressed in CD8 T-cells in the colon, which outnumber CD4 T-
cells. Foxp3+ Treg were present at a modest percentage in the CD4 LPL population (around 
5%) and were vastly outnumbered by Foxp3-negative CD4 and CD8 T-cells, mostly Trm, 
expressing high levels of CD39 and CD73. Arguably the low number of Foxp3+ Treg in human 
colon is insufficient to maintain tolerance in the presence of such large antigenic loads from 
the microbiota, necessitating accumulation of Trm populations with regulatory capacity. 
Since Trm do not differentiate until they reach the tissue34, this would explain why we found 
tolerance to commensal bacteria was not systemic, but localized to the gut. Circulating T-
cells reactive to commensals would not express regulatory function until resident in the 
tissue and would require local tissue factors such as type I IFN and AhR agonists to maintain 
their function. This picture contrasts with that emerging from mouse models, most likely 
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due to far greater antigenic experience and maturity of the adult human immune system 
compared to laboratory mice. We found higher proportions of conventional CD8αβ T-cells in 
tissue than reported in mice, which may rely more on innate mechanisms and thymus-
derived Foxp3+ Treg due to their short lifespan. We also found strong correlation between 
αβ+ and γδ+ T-cells in IEL, implying αβ+ may support γδ+ cell populations in a fashion 
analogous to that demonstrated in the thymus35, or co-dependence on tissue-specific 
environmental factors. A further correlation was shown between numbers of memory CD8 
responses to commensal bacteria and colonic CD8 Trm, suggesting that such responses are 
required to recruit and maintain healthy Trm populations. CD8 Trm have recently been 
shown to be recruited to skin in response to skin resident microbes in a non-classical MHC-
restricted fashion36. This mouse study demonstrated that such Trm exhibited an unusual 
phenotype with expression of immunoregulatory genes and wound-healing activity, thus 
improving barrier function without inflammation. Our data suggest a similar phenomenon 
occurs in the colon but is dependent on classical responses to a wide range of bacterial 
antigens. 
One recent study demonstrated a pro-inflammatory role for Trm cells in active IBD37, thus 
suggesting that Trm can exhibit both pro- and anti-inflammatory activities dependent on the 
context. CD4 and CD8 Trm were increased in the lamina propria of inflamed IBD tissue in 
this study, and T-cell transfer colitis experiments in mice confirmed that T-cells adopt a Trm 
phenotype soon after recruitment to lamina propria in active disease37. The pathologic role 
of Trm was dependent on their pro-inflammatory cytokine production regulated by 
Hobit/Blimp-1 transcription factors expressed in Trm. However, deletion of Hobit/Blimp-1 in 
mouse CD4 T-cells had no effect on their regulatory function or development into Trm37. A 
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further study compared proportions of CD103+ cells within total T cell populations in 
inflamed vs uninflamed biopsies from CD and UC patients38. This study showed decreased 
proportions of CD103+ cells in inflamed tissue; however this could have been due to influx of 
effector memory-type cells. Further work in murine systems targeting regulatory function in 
Trm and effects on disease susceptibility are therefore warranted. We propose that dual 
functionality of Trm cells in homeostatic versus inflammatory conditions would allow 
balanced immunity to occur across large areas of tissue exposed to high antigenic loads. 
Murine studies have not clearly described the biology of CD4+ Trm and unlike CD8 cells, 
Runx3 expression in human CD103+ CD4 cells in LPL was low, so we focussed on CD8+ Trm 
activities. Dietary factors retinoic acid and AhR agonists could play a role in expression of 
the Trm phenotype within tissue or in Trm survival, in addition to the mucosal cytokine TGF-
β and type 1 interferon, both cytokines associated with suppression of colitis13,39-41. Gut type 
1 interferon production could be influenced by the enteric virome, which is also altered in 
IBD42. ATRA is derived from vitamin A by antigen-presenting cells39 while AhR agonists are 
dietary factors contained in cruciferous vegetables and key to gut health15. Combining these 
factors in vitro allowed us to develop the first in vitro differentiation model for human Trm, 
but also revealed distinct regulation of individual Trm-associated markers. Interestingly, 
although CD103 expression was entirely dependent on TGF-β, the key Trm transcription 
factor Runx3, and CD39 were unaffected by TGF-β and co-regulated by type 1 interferon and 
the AhR agonist. Thus CD103, as a migration marker, may not necessarily reflect Trm 
function in clinical studies. 
Circulating IgG antibody to certain commensals was increased in CD but not UC, despite B-
cell dysfunction in UC with increased circulating plasmablasts and IgA secretion. Since 
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inflammatory lesions penetrate deeper into intestinal tissue in CD than UC43, and there is 
more involvement of mesenteric lymph nodes in CD than UC44,45, it is possible that longer-
lived, higher affinity antibody responses are generated in CD as antigens could access 
germinal centres in lymph nodes driving affinity maturation. Circulating B-cell proliferative 
responses may reflect shorter term responses with more broadly reactive antibody 
synthesis focussed on mucosa. Indeed, repeat assays on individual healthy donors showed 
memory responses to commensal bacteria could change within a year, and long-term 
memory is not required for non-pathogenic organisms. The excessive IgA response to 
mucosa-associated microbes was apparent in both CD and UC but was not accompanied by 
increased circulating Tfh-like cells. Future work could examine microbe-specific Tfh cells but 
these might be sequestered in lymphoid tissue. 
Mechanisms through which CD8 T-cells might control immune deviation are not entirely 
clear, but they are known to regulate CD4 T-cell development. Here CD4 responses were not 
altered in IBD, but we did not examine their cytokine profiles, which are skewed towards a 
Th17 profile in IBD4. Th17 development is strongly inhibited by IFN-γ46, the major product of 
CD8 T-cells. Our data show an additional mechanism could be via induction of T-bet in DCs, 
either via interaction with tissue-resident T-cells reactive to microbial antigens, or in 
draining lymphoid tissues. T-bet expression in DC is critical in preventing colitis in mice, 
since it represses production of TNF-α18,47. Consistent with this concept, we found 
interaction with T-cells suppressed TNF-α in pDC whilst enhancing IFN-α production in DC, 
although these effects were less specific to T-cells and IFN-γ. This novel pathway may 
contribute to immune deviation and allow acquired immune memory to reinforce DC 
activity in tissues. Dialogue between Trm and DC in tissue may inform appropriate type of 
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memory response as well as directing tissue migration of effector cells. Current dogma 
states that DC direct T-cell responses after integrating signals from innate immunity and 
tissue damage. However, additional dialogue between tissue DC and Trm would allow for 
more intelligent decision-making based on host immunological experiences, thus allowing 
the gut immune system to learn which bacteria are pathogenic over time. 
IBD is a clear example of a “western” disease associated with dysbiosis and disrupted 
immunoregulation48. Our data establish IBD as a disease of B-cell dysfunction and point 
towards deficient CD8 T-cell priming to the microbiota as key to its etiology. IBD often 
exhibits extra-intestinal manifestations49, and several other diseases are associated with 
intestinal dysbiosis. It is therefore possible that reduced Trm-priming is a general 
mechanism underlying the hygiene hypothesis in immune-mediated disease, and 
associations of microbiota with tumour development and cancer therapy50,51. Memory CD8 
T-cells migrate to multiple tissues and escape homeostatic control mechanisms that limit 
their numbers in the circulation52, so numbers of Trm can accumulate throughout life in 
response to immunological experiences. Notably, CD8 Trm accumulate throughout 
childhood in humans53, when IBD is often first diagnosed. Since CD8 responses are typically 
utilized for dealing with highly pathogenic organisms, a lack of exposure to enteric 
pathogens in early life could result in weakened tissue immunity and thus an altered 
microbiota. Evidence for this in IBD was provided by the increased antibody response to VZV 
seen in CD. VZV is latent and requires constant immune surveillance by cytotoxic T-cells; 
thus increased antibody may reflect weaker cytotoxic control of virus, although this was not 
the case for measles and RSV.  
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Manipulating immunity to intestinal microbiota through vaccination may address the 
underlying disease process, unlike current immunosuppressive strategies. It may prove of 
greater therapeutic benefit than changing the microbiota itself in a range of diseases 
associated with dysbiosis, since every patient will respond differently to any particular 
microbe/cohort due to MHC differences. Mice which lack T-bet expression in their innate 
immune system develop altered microbiota which is colitogenic18, indicating dysbiosis is 
secondary to immune changes. Vaccination would need specifically to target CD8 T-cell 
responses; inducing cytotoxic activity against target microbes may eliminate them from the 
microbiota, thus preventing pathology. The concept that immunization to induce CD8 T-cell 
responses can suppress inflammatory pathology may be counterintuitive, but proof of 
principle for this was demonstrated in mouse models of airway disease54,55. Such 
vaccination could provide long-lasting effects on the highly plastic DCs that direct immune 
responses into pathways associated with health or disease. 
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Figure Legends 
 
Figure 1. Human colonic Trm are identified by CD103 and express Runx3, T-bet and 
regulatory T-cell markers but not Foxp3. A: CD8 T-cell and γδ T-cell populations were 
identified in IEL fractions and stained for CD69/CD103 surface Trm markers; gated CD103+ 
cells were stained for intranuclear Runx3 and T-bet. B: CD4 and CD8 T-cell populations were 
identified in LPL fractions and stained for CD69/CD103; gated CD103+ cells were stained for 
Runx3 and T-bet. C: IEL CD8+ and γδ T-cell populations were stained for CD39/CD73 Treg-
associated ectonucleotidases and CD8αβ to distinguish conventional vs innate-type 
lymphocytes. CD8αβ and CD8αα subsets were separately gated and T-bet and Runx3 
expression shown, including isotype control staining for transcription factors. D: LPL CD4+ 
and CD8+ Trm-like populations were stained for surface CD39/CD73 and intranuclear Foxp3. 
Right panels show isotype control for Foxp3 stain. Staining is from right colon biopsies of 
healthy donors and is representative of at least 5 individual donors. Similar data were 
obtained in left colon.   
Figure 2. Quiescent IBD is associated with reduced numbers of Trm and γδ T-cells in colonic 
tissue. A: Numbers and percentages of CD8+ γδ TCR- CD103+ Trm recovered from IEL (upper 
graphs) and γδ CD103+ T-cells in IEL (lower graphs), alongside CD39 and CD73 expression on 
these populations. B: Numbers and percentages of CD4+ CD103+ Trm (upper graphs) and 
CD8+ CD103+ Trm (lower graphs) recovered from LPL, alongside CD39 and CD73 expression. 
Full gating strategies are shown in supplementary methods. C: Total live cell numbers in IEL 
and LPL fractions (including epithelial cells). D: Correlation of CD8 Trm and γδ T-cell numbers 
in IEL populations from right colon biopsies of all donors. HC: healthy controls, n=25; CD: 
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Crohn’s disease, n=12; UC: ulcerative colitis, n=20. Median values ± 95% confidence 
intervals are shown; statistically significant differences between groups (Kruskal-Wallis test) 
are indicated. Spearman correlation coefficient was calculated in D. 
Figure 3. Human CD8 Trm development in vitro is regulated by cytokines, vitamins and 
dietary factors. A: Effects of combinations of TGF-β, IFN-β, all-trans retinoic acid (ATRA) and 
an AhR agonist (FICZ) on Trm, Treg and homing markers in CD8 effector cells derived from 
CD8 naïve T-cells differentiated with anti-CD3/CD28+IL-2 for 7 days. Graphs show mean ± 
SEM from 5 independent experiments; groups compared using 1-way ANOVA with Dunn’s 
test for multiple comparisons applied. B: Cells expressing all Trm-associated markers 
simultaneously were analyzed as in A. C: Staining profiles as in A, showing example of cells 
cultured in anti-CD3/28 + IL-2 only (Tc1 cells) or with addition of TGF-β, IFN-β, ATRA and 
FICZ (Trm-like cells). 
Figure 4. Immunopathology of quiescent IBD reflects B-cell dysregulation. A: Proportions of 
Tfh-like (CXCR5+) CD4/CD8 T-cells and gut homing (integrin-β7+) T-cells in PBMC of healthy 
control and IBD donors. B: Circulating plasmablasts (CD38hi CD27+ CD19+) and B-cell subsets 
in healthy and IBD donors. Kruskal-Wallis tests were used to compare groups (n=23 HC; 
n=18 CD; n=17 UC). C: IgA coating of IEM obtained from right colon biopsies of example HC, 
CD and UC donors, after gating on SYBR Green+ events. D: Pooled data showing proportions 
of IgA+ IEM in donor groups. 1-way ANOVA was used to compare groups (n=25 HC; n=9 CD; 
n=19 UC). 
Figure 5. T- and B-cell memory responses to commensal bacteria show skewing from cell-
mediated to humoral immunity in IBD. A: CD4 and CD8 T-cell memory responses to selected 
commensals in healthy PBMC, showing examples of CellTrace Violet dilution in CD4/CD8-
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gated populations in cultures showing positive and negative responses alongside SEB 
positive control; integrin-β7 staining indicates gut-homing potential of expanded antigen-
specific cells. B: CD19+ B-cell responses to selected commensals in example CD and UC 
patient PBMC; as in A but gated on CD19+ events. C: Representative proliferation data in 
PBMC from a HC, CD and UC donor, showing responses to a panel of 19 bacteria after 7 days 
stimulation and gating for CD4+ CD8+ and CD19+ cells. D: Pooled data as in C, showing 
numbers of positive responses within panel of 19 commensals. Kruskal-Wallis tests were 
used to compare groups; n=18 HC, n=16 CD&UC. E: Correlation of CD8 proliferative 
responses in PBMC with CD8 Trm in IEL from autologous biopsies (n=15). Upper panel shows 
pooled data with lower panels showing individual correlations for HC and IBD samples. F: 
Magnitude of proliferative responses to 4 individual species, one from each phylum. 
Pearson correlation coefficient was calculated in E. 
Figure 6. Circulating specific IgG antibodies to immunogenic commensal species are raised in 
CD but not UC donors. A: Plasma was assayed for IgG antibodies using a coating assay. 
Ratios of median fluorescence intensity of anti-IgG-stained vs isotype control for each 
sample are shown (median and 95% CIs). Kruskal-Wallis tests were used to compare groups; 
n=30 HC, n=18 CD&UC. B: Correlation of B-cell proliferative responses to E. coli against 
circulating IgG in 40 matched donors, including Pearson correlation coefficient. Correlations 
with other species were not significant. C: Antibodies against non-enteric viruses in health 
vs IBD. Plasma were assayed by ELISA for IgG to viral antigens and results expressed in 
arbitrary units. Grey lines represent cut-off points below which titres are considered 
negative. 1-way ANOVA was used to compare groups. 
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Figure 7. Mechanisms of immune deviation in IBD. A: Trm-like cells have Treg function 
partially dependent on CD39 nucleotidase activity - Tc1 or Trm-like cells were added to 
autologous fluorescent labelled PBMC and suppression of CD8 target cell activation was 
determined in the presence or absence of the CD39 inhibitor ARL67156. Example staining 
and pooled data showing % suppression of proliferation from 3 independent experiments - 
mean±SEM, paired t-tests used to compare groups. B: Trm-like cells have increased capacity 
for IL-10 secretion. Tc1 and Trm-like cells were restimulated with PMA/ionomycin/monensin 
and stained for intracellular cytokines. Example staining and pooled data showing % staining 
from 4 independent experiments - mean±SEM, paired t-tests used. C: Induction of T-bet 
expression in DC by cognate interaction with T-cells mediated by superantigen is associated 
with altered cytokine synthesis - PBMC were cultured overnight with LPS or SEB plus control 
antibody/anti-IFN-γ, followed by 4h with LPS+poly I:C+monensin. mDC/pDC populations 
were gated according to CD11c/CD123 expression after gating on singlet, viable DC using 
lineage vs HLA-DR plots. Example staining and pooled data from 4-5 independent 
experiments is shown; paired t-tests were used to compare groups. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz175/5607395 by U
niversity of East Anglia user on 04 N
ovem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz175 
 
Table 1a. Clinical characteristics of St Mark’s Hospital colonoscopy patients 
donating colonic biopsies  
Characteristic HC CD UC 
    
n 23 11 18 
Male/female 13/10 4/7 12/6 
Median age (95% CI) at sampling 51.5 (41-57) 43 (28-57) 53.5 (47-60) 
Median age (95% CI) at diagnosis    26 (18-47) 35 (29-42) 
    
    
Inflammation – endoscopic subscores for UC:    
    
Mayo 0   8 
Mayo 1   3 
Mayo 2   6 
Mayo 3   1 
    
IBD Medications at sampling:    
Aminosalicylates  4 15 
Azathioprine/6-mercaptopurine  4 1 
Buscopan  1 0 
Adalimumab  1 0 
None  4 3 
    
Non-IBD medications at sampling:    
Metformin/gliclazide/statin  0 2 
Ondansetron  1 0 
Certirazine  1 0 
None  9 16 
    
    
    
    
    
    
    
Demographic and clinical data analyzed in Figs 2, 4d, S1 
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Table 1b. Clinical features/Montreal classification of CD patients donating 
colonic biopsies  
Donor Age at 
diagnosis 
Disease 
location 
Disease 
behaviour 
Inflammation 
     
1 A2 L3 B1 none 
2 A3 L3 B1 mucosal erosions, polyps 
3 A2 L2 B1 patchy area of 
inflammation, polyps 
4 A1 L0 B1 none 
5 A2 L3 B1 small mucosal ulceration 
6 A2 L3 B1 ulceration, scarred colon 
7 A3 L3 B1 ulceration 
8 A2 L0 B1 none 
9 A2 L0 B1 none 
10 A2 L0 B1 none 
11 A2 L3 B1 mild 
inflammation/ulceration 
     
     
Demographic and clinical data analyzed in Figs 2, 4d, S1 
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Table 2. Clinical characteristics of St Mark’s Hospital blood donors and 
healthy volunteers  
Characteristic HC CD UC 
    
n 18 17 14 
Male/female 13/5 8/9 7/7 
Median age (95% CI) at sampling 41.5 (30-54) 43.5 (33-61) 54.5 (35-63) 
Median age (95% CI) at diagnosis    25 (20-44) 38.5 (25-47) 
    
Symptoms at sampling:    
Diarrhoea/loose stools  1 2 
Occasional loose motion/watery stool  2 1 
Abdominal pain  2 1 
Peri-anal pain/itch/disease  2 1 
Lethargy  2 0 
Proctitis  0 1 
None  9 8 
    
IBD Medications at sampling:    
Aminosalicylates  8 8 
Azathioprine/6-mercaptopurine  8 2 
Corticosteroids  1 0 
Vedolizumab  1 0 
Antibiotics  1 0 
Methotrexate  1 0 
None  1 6 
    
Non-IBD medications at sampling:    
Vitamins D/D3/B12/multi  4 3 
Metformin/gliclazide  0 2 
Statins  1 2 
Hydroxychloroquine  0 1 
Proton pump inhibitor  0 1 
Alendronate  1 0 
Finasteride  1 0 
Loperamide  1 1 
None  12 9 
    
    
Demographic and clinical data analyzed in Figs 4,5, S2, S3, S4 
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